

antibodies is mediated through catalyzing of the hydrolysis
of cellular chemical bonds.

Claim 5. The anti-cancer antibodies or fragments thereof
in accordance with claim 1 wherein the cytotoxicity of said
antibodies is mediated through producing an immune response
against putative cancer antigens residing on tumor cells.

Claim 6. The anti-cancer antibodies or fragments thereof
in accordance with claim 1 wherein the cytotoxicity of said
antibodies is mediated through targeting of cell membrane
proteins to interfere with their function.

Claim 7. The anti-cancer antibodies or fragments thereof
in accordance with claim 1 wherein the cytotoxicity of said
antibodies is mediated through production of a conformational
change in a cellular protein effective to produce a signal to
initiate cell-killing.

Claim 8. The anti-cancer antibodies of claim 1 wherein:
said method of production utilizes a tissue sample
obtained from a particular individual containing cancerous
and non-cancerous cells.

Claim 9. Anti-cancer antibodies or fragments thereof
selected from the group consisting of a 3BD-3, a 3BD-6, a

3BD-8, a 3BD-9, a 3BD-15, a 3BD-25, a 3BD-26 and a 3BD-27
monoclonal antibody.

Claim 10. Anti-cancer antibodies or fragments thereof
produced by a hybridoma cell line having an ATCC Accession
Number selected from the group consisting of ().

Claim 11. Anti-cancer antibodies or fragments thereof
selected from the group consisting of a 1LN-1, a 1LN-12, a
1LN-14, a 2LN-21, a 2LN-28, a 2LN-29, a 2LN-31, a 2LN-33, a
2LN-34 and a 2LN-35 monoclonal antibody.

Claim 12. Anti-cancer antibodies or fragments thereof
produced by a hybridoma cell line having an ATCC Accession
Number selected from the group consisting of ().